Massachusetts Financial Services Co. MA bought a new stake in shares of CeriBell (NASDAQ:CBLL - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 415,361 shares of the company's stock, valued at approximately $10,750,000. Massachusetts Financial Services Co. MA owned approximately 1.16% of CeriBell at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently modified their holdings of CBLL. Vanguard Group Inc. bought a new stake in CeriBell during the 4th quarter valued at approximately $18,015,000. Franklin Resources Inc. bought a new stake in shares of CeriBell during the fourth quarter valued at approximately $12,460,000. Geode Capital Management LLC purchased a new stake in CeriBell in the fourth quarter worth $6,654,000. Emerald Advisers LLC purchased a new stake in CeriBell in the fourth quarter worth $3,126,000. Finally, Charles Schwab Investment Management Inc. bought a new position in CeriBell in the fourth quarter worth $2,500,000.
CeriBell Price Performance
CeriBell stock traded up $3.85 during mid-day trading on Friday, reaching $15.00. The stock had a trading volume of 2,298,090 shares, compared to its average volume of 264,322. CeriBell has a one year low of $10.01 and a one year high of $32.75. The company's 50-day moving average price is $21.04.
CeriBell (NASDAQ:CBLL - Get Free Report) last issued its earnings results on Tuesday, February 25th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.08). The firm had revenue of $18.53 million for the quarter, compared to analysts' expectations of $17.55 million. On average, equities analysts expect that CeriBell will post -2.46 EPS for the current fiscal year.
Analysts Set New Price Targets
A number of analysts have recently commented on the stock. LADENBURG THALM/SH SH began coverage on shares of CeriBell in a report on Friday, April 4th. They set a "buy" rating and a $32.00 target price on the stock. Canaccord Genuity Group reissued a "buy" rating and set a $33.00 price objective on shares of CeriBell in a research note on Wednesday, February 26th. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $32.50.
Check Out Our Latest Stock Analysis on CeriBell
About CeriBell
(
Free Report)
We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.
Further Reading
Before you consider CeriBell, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CeriBell wasn't on the list.
While CeriBell currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
